Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and Rani Therapeutics (NASDAQ:RANI – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.
Earnings and Valuation
This table compares Taysha Gene Therapies and Rani Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Taysha Gene Therapies | $7.47 million | 252.32 | -$109.00 million | ($0.38) | -17.26 |
| Rani Therapeutics | $1.63 million | 60.19 | -$29.67 million | ($0.41) | -1.93 |
Volatility & Risk
Taysha Gene Therapies has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.
Profitability
This table compares Taysha Gene Therapies and Rani Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Taysha Gene Therapies | N/A | -56.07% | -40.16% |
| Rani Therapeutics | N/A | -206.46% | -83.95% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Taysha Gene Therapies and Rani Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Taysha Gene Therapies | 1 | 0 | 11 | 2 | 3.00 |
| Rani Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
Taysha Gene Therapies currently has a consensus target price of $12.77, indicating a potential upside of 94.65%. Rani Therapeutics has a consensus target price of $8.75, indicating a potential upside of 1,004.80%. Given Rani Therapeutics’ higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than Taysha Gene Therapies.
Institutional & Insider Ownership
77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 3.5% of Taysha Gene Therapies shares are held by insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Taysha Gene Therapies beats Rani Therapeutics on 10 of the 14 factors compared between the two stocks.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
About Rani Therapeutics
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
